Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 09:06 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone
NCT01702701 · Medical College of Wisconsin · PHASE3 · withdrawn · last registry update 2019-08-28 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Medical College of Wisconsin |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CYSLTR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-05-15Phase 3 first posted: McGill University, Montelukast 10mg (NCT04389411)
- 2020-04-17Phase 3 first posted: Great Ormond Street Hospital for Children NHS Foundation Trust, Montelukast (NCT04351698)
- 2020-03-27Phase 3 first posted: Hanmi Pharmaceutical Company Limited, HCP1102 + HGP1408 (NCT04324918)
- 2020-02-20Phase 3 first posted: Jagiellonian University, Montelukast 10mg + Standard anti-platelet treatment (NCT04277702)
- 2020-02-17Phase 3 first posted: Sanofi, Isatuximab SAR650984 + Lenalidomide (NCT04270409)
- 2019-12-18Also stopped (terminated): Brighton and Sussex University Hospitals NHS Trust, Montelukast or Salmeterol or Theophylline or Steroid (NCT03269318)
- 2019-10-02Results posted on the registry: Memorial Sloan Kettering Cancer Center, carboplatin + carboplatin (NCT01248962)
- 2019-10-01Results posted on the registry: University of California, San Francisco, zafirlukast (NCT02950480)
- 2019-10-01Also stopped (terminated): University of California, San Francisco, zafirlukast (NCT02950480)
- 2019-07-12Results posted on the registry: Menarini International Operations Luxembourg SA, Bilastine 20mg + Montelukast 10mg (NCT02761252)
- 2019-05-03Results posted on the registry: University of Chicago, Montelukast (NCT01027806)
- 2019-05-03Also stopped (terminated): University of Chicago, Montelukast (NCT01027806)
- 2019-03-26Results posted on the registry: Vanderbilt University Medical Center, Montelukast added to Hydroxyurea + Placebo added to Hydroxyurea (NCT01960413)
- 2019-01-14Results posted on the registry: Maruho Europe Limited, Montelukast + ASP2151 (NCT02321748)
- 2018-12-10Phase 3 first posted: Sherief Abd-Elsalam, Rupatadine + Montelukast (NCT03770923)
- 2018-12-03Results posted on the registry: Romaker & Associates, budesonide and montelukast + Placebo (NCT01089647)
- 2018-11-23Results posted on the registry: Merck Sharp & Dohme LLC, MK-1029 + Placebo (NCT01624974)
- 2018-09-13Results posted on the registry: Merck Sharp & Dohme LLC, MK-1029 + Montelukast 10 mg (NCT01656395)
- 2018-09-13Also stopped (terminated): Merck Sharp & Dohme LLC, MK-1029 + Montelukast 10 mg (NCT01656395)
- 2018-08-28Results posted on the registry: Merck Sharp & Dohme LLC, MK-1029 150 mg + MK-1029 Matching-image Placebo (NCT02720081)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision